Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association
Scope
As issued by the authors
Guidance for health care professionals and people with diabetes and/or obesity on compounded GLP-1 RA and dual GIP/GLP-1 RA products in circumstances of medication unavailability, to promote optimal care and medication use safety
Original publication
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. Published 2 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →